Pharmaceutical Research Unit (PRU) is pleased to announce the renewal of its accreditation with the National Pharmaceutical Regulatory Agency (NPRA). This extension confirms PRU’s certification until 6 July 2025, reinforcing its commitment to high-quality standards in the clinical trials industry.
Established in 1993, PRU is a leader in bioequivalence studies, offering services such as clinical trials setup, bioanalysis, and data management. The renewed NPRA accreditation underscores PRU’s dedication to regulatory compliance and excellence.
“We are thrilled with this accreditation extension,” said a PRU spokesperson. “It reaffirms our commitment to quality research and strict regulatory standards. We will continue providing the best service to our clients.”
The NPRA’s endorsement validates PRU’s operations, ensuring precise and reliable clinical trials and bioequivalence studies. This certification strengthens PRU's mission to support pharmaceutical companies in bringing safe and effective medications to market.
